← 返回专利悬崖列表
CAS 7689-03-4
(S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
登记编号：BELOH-017
应用背景（按来源药适应症）
非小细胞肺癌盐酸贝洛替康卵巢癌盐酸贝洛替康实体瘤盐酸贝洛替康
来源药（使用该中间体的合成路线）
| 品种 | 梯队 | 到期年 |
|---|---|---|
| 盐酸贝洛替康Belotecan Hydrochloride | Tier C · 观察 / 贸易 | - |
合成路线中的位置（上下游链）
按路线登记顺序排列，左→右为合成方向；高亮为当前 CAS，其余可点击跳转对应档案。
(S)-4-ethyl-4-hydroxy-7,8-dihydro-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione→4-ethyl-1,4,7,8-tetrahydro-3H,10H-spiro[pyrano[3,4-f]indolizine-6,2'-[1,3]dioxolane]-3,10-dione→4-ethyl-3-hydroxy-3,4,7,8-tetrahydro-1H,10H-spiro[pyrano[3,4-f]indolizine-6,2'-[1,3]dioxolan]-10-one→4-ethyl-7,8-dihydro-1H,10H-spiro[pyrano[3,4-f]indolizine-6,2'-[1,3]dioxolan]-10-one→(4S)-4-ethyl-3,4-dihydroxy-3,4,7,8-tetrahydro-1H,10H-spiro[pyrano[3,4-f]indolizine-6,2'-[1,3]dioxolan]-10-one→(4S)-4-ethyl-4-hydroxy-10-oxo-4,7,8,10-tetrahydro-1H,3H-spiro[pyrano[3,4-f]indolizine-6,2'-[1,3]dioxolan]-3-yl acetate→(4S)-4-ethyl-4-(methoxymethoxy)-10-oxo-4,7,8,10-tetrahydro-1H,3H-spiro[pyrano[3,4-f]indolizine-6,2'-[1,3]dioxolan]-3-yl acetate→(4S)-4-ethyl-3-hydroxy-4-(methoxymethoxy)-3,4,7,8-tetrahydro-1H,10H-spiro[pyrano[3,4-f]indolizine-6,2'-[1,3]dioxolan]-10-one→(S)-4-ethyl-4-(methoxymethoxy)-1,4,7,8-tetrahydro-3H,10H-spiro[pyrano[3,4-f]indolizine-6,2'-[1,3]dioxolane]-3,10-dione→(S)-4-ethyl-4-hydroxy-1,4,7,8-tetrahydro-3H,10H-spiro[pyrano[3,4-f]indolizine-6,2'-[1,3]dioxolane]-3,10-dione→2-(1,3-dioxolan-2-yl)aniline→(S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione→(S)-4-ethyl-4-hydroxy-11-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione
(S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione→(S)-4-ethyl-4-hydroxy-11-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione→2,4,6,8-tetramethyl-1,3,5,7-tetraoxocane→1,3,5-trioxane
本站可供应的对应中间体
目录暂未收录该靶点的在售中间体 —— 可直接发起询价，需求会进入撮合池。
本页为中间体 CAS 注册档案：同 CAS 的多条路线登记已合并；后续供应商报价与买方需求以该 CAS 为主键撮合。